112 related articles for article (PubMed ID: 10762335)
1. Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum.
Tzavara ET; Valjent E; Firmo C; Mas M; Beslot F; Defer N; Roques BP; Hanoune J; Maldonado R
Eur J Neurosci; 2000 Mar; 12(3):1038-46. PubMed ID: 10762335
[TBL] [Abstract][Full Text] [Related]
2. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
Tsou K; Patrick SL; Walker JM
Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
[TBL] [Abstract][Full Text] [Related]
3. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
4. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940.
Rubino T; Viganò D; Massi P; Parolaro D
J Neurochem; 2000 Nov; 75(5):2080-6. PubMed ID: 11032897
[TBL] [Abstract][Full Text] [Related]
5. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
Cook SA; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
[TBL] [Abstract][Full Text] [Related]
6. Nicotine withdrawal syndrome: behavioural distress and selective up-regulation of the cyclic AMP pathway in the amygdala.
Tzavara ET; Monory K; Hanoune J; Nomikos GG
Eur J Neurosci; 2002 Jul; 16(1):149-53. PubMed ID: 12153540
[TBL] [Abstract][Full Text] [Related]
7. delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory.
Wise LE; Varvel SA; Selley DE; Wiebelhaus JM; Long KA; Middleton LS; Sim-Selley LJ; Lichtman AH
Psychopharmacology (Berl); 2011 Oct; 217(4):485-94. PubMed ID: 21559804
[TBL] [Abstract][Full Text] [Related]
8. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol.
Hutcheson DM; Tzavara ET; Smadja C; Valjent E; Roques BP; Hanoune J; Maldonado R
Br J Pharmacol; 1998 Dec; 125(7):1567-77. PubMed ID: 9884086
[TBL] [Abstract][Full Text] [Related]
9. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal.
Rodríguez de Fonseca F; Carrera MR; Navarro M; Koob GF; Weiss F
Science; 1997 Jun; 276(5321):2050-4. PubMed ID: 9197270
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
Aceto MD; Scates SM; Lowe JA; Martin BR
Eur J Pharmacol; 1995 Aug; 282(1-3):R1-2. PubMed ID: 7498260
[TBL] [Abstract][Full Text] [Related]
11. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments.
Rubino T; Viganò D; Zagato E; Sala M; Parolaro D
Synapse; 2000 Jan; 35(1):8-14. PubMed ID: 10579803
[TBL] [Abstract][Full Text] [Related]
12. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Tanda G; Loddo P; Di Chiara G
Eur J Pharmacol; 1999 Jul; 376(1-2):23-6. PubMed ID: 10440085
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
15. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
Beardsley PM; Martin BR
Eur J Pharmacol; 2000 Jan; 387(1):47-53. PubMed ID: 10633159
[TBL] [Abstract][Full Text] [Related]
16. Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.
Trexler KR; Nass SR; Crowe MS; Gross JD; Jones MS; McKitrick AW; Siderovski DP; Kinsey SG
Drug Alcohol Depend; 2018 Oct; 191():14-24. PubMed ID: 30071445
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice.
Valverde O; Maldonado R; Valjent E; Zimmer AM; Zimmer A
J Neurosci; 2000 Dec; 20(24):9284-9. PubMed ID: 11125007
[TBL] [Abstract][Full Text] [Related]
18. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells.
Rubovitch V; Gafni M; Sarne Y
Brain Res Mol Brain Res; 2002 May; 101(1-2):93-102. PubMed ID: 12007836
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
20. Heterologous sensitization of adenylate cyclase is protein kinase A-dependent in Cath.a differentiated (CAD)-D2L cells.
Johnston CA; Beazely MA; Vancura AF; Wang JK; Watts VJ
J Neurochem; 2002 Sep; 82(5):1087-96. PubMed ID: 12358756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
